Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC.
AZD7442
Allogeneic stem cell transplantation
Pre-exposure prophylaxis
SARS-CoV-2
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
28 11 2022
28 11 2022
Historique:
received:
25
09
2022
accepted:
09
11
2022
entrez:
29
11
2022
pubmed:
30
11
2022
medline:
1
12
2022
Statut:
epublish
Résumé
Since the emergence of the Omicron variant of SARS-CoV-2, though considered less virulent, hospitalization and death rates among immunocompromised patients remain high, especially for poor responders to vaccination. We conducted a retrospective multicentric study to evaluate pre-exposure prophylaxis with AZD7442 (tixagevimab/cilgavimab) for preventing COVID-19 in adult allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. Among the 161 patients of our cohort, 22 (14%) contracted COVID-19 after a median follow-up of 105 days, but no severe form was observed. Only one major adverse event was reported: an acute coronary syndrome, resolved without sequelae. Pending randomized controlled trial results, our data support the use of AZD7442 as pre-exposure prophylaxis for COVID-19 during Omicron wave in allo-HSCT patients who failed to develop humoral immunity to vaccination, to prevent severe and potentially lethal forms of SARS-CoV-2 infection.
Identifiants
pubmed: 36443846
doi: 10.1186/s13045-022-01387-0
pii: 10.1186/s13045-022-01387-0
pmc: PMC9702670
doi:
Substances chimiques
tixagevimab
0
cilgavimab
1KUR4BN70F
cilgavimab and tixagevimab drug combination
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
169Informations de copyright
© 2022. The Author(s).
Références
Am J Transplant. 2022 Dec;22(12):3130-3136
pubmed: 35727916
Cancer Cell. 2022 Jun 13;40(6):590-591
pubmed: 35598602
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Clin Infect Dis. 2022 Jul 29;:
pubmed: 35904210
Lancet Respir Med. 2022 Oct;10(10):985-996
pubmed: 35688164
Br J Haematol. 2021 Mar;192(5):e121-e124
pubmed: 33522598
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
Clin Microbiol Infect. 2022 Dec;28(12):1654.e1-1654.e4
pubmed: 35926762
Am J Transplant. 2022 Nov;22(11):2675-2681
pubmed: 35713984